Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Other Non-Current Assets (2020 - 2025)

Historic Other Non-Current Assets for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to $2.3 million.

  • Relay Therapeutics' Other Non-Current Assets rose 655.97% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 655.97%. This contributed to the annual value of $2.1 million for FY2024, which is 2172.15% down from last year.
  • According to the latest figures from Q3 2025, Relay Therapeutics' Other Non-Current Assets is $2.3 million, which was up 655.97% from $2.3 million recorded in Q2 2025.
  • In the past 5 years, Relay Therapeutics' Other Non-Current Assets ranged from a high of $2.7 million in Q2 2023 and a low of $878000.0 during Q1 2021
  • Over the past 5 years, Relay Therapeutics' median Other Non-Current Assets value was $2.6 million (recorded in 2021), while the average stood at $2.4 million.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first soared by 19362.19% in 2021, then tumbled by 2172.15% in 2024.
  • Over the past 5 years, Relay Therapeutics' Other Non-Current Assets (Quarter) stood at $2.6 million in 2021, then changed by 0.0% to $2.6 million in 2022, then increased by 5.0% to $2.7 million in 2023, then fell by 21.72% to $2.1 million in 2024, then rose by 6.56% to $2.3 million in 2025.
  • Its Other Non-Current Assets stands at $2.3 million for Q3 2025, versus $2.3 million for Q2 2025 and $2.1 million for Q1 2025.